Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19

(2023) Kevin E. Kip et al.   ANNALS OF INTERNAL MEDICINE

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool

(2022) Valerie Schmieder et al.   JOURNAL OF BIOTECHNOLOGY

Preclinical and clinical developments for combination treatment of influenza

(2022) Paulina Koszalka et al.   PLoS Pathogens

Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

(2022) Kara W. Chew et al.   Nature Communications

Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products

(2022) Brian Kelley et al.   CURRENT OPINION IN BIOTECHNOLOGY

Nirsevimab: First Approval

(2022) Susan J. Keam   DRUGS

Subcloning induces changes in the DNA‐methylation pattern of outgrowing Chinese hamster ovary cell colonies

(2021) Marcus Weinguny et al.   Biotechnology Journal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tracing production instability in a clonally derived CHO cell line using single‐cell transcriptomics

(2021) Ioanna Tzani et al.   BIOTECHNOLOGY AND BIOENGINEERING

Landscape of Monoclonal Antibodies Targeting Zika and Dengue: Therapeutic Solutions and Critical Insights for Vaccine Development

(2021) Vincent Dussupt et al.   Frontiers in Immunology

End‐to‐end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies

(2021) Hanna Mahal et al.   BIOTECHNOLOGY AND BIOENGINEERING

Naming CHO cells for bio‐manufacturing: Genome plasticity and variant phenotypes of cell populations in bioreactors question the relevance of old names

(2021) Maria J. Wurm et al.   Biotechnology Journal

The Pandemic and Resilience for the Future: AccBio 2021

(2021) Āine T. McGovern et al.   BIOTECHNOLOGY PROGRESS

Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak

(2021) Zheng Zhang et al.   BIOTECHNOLOGY PROGRESS

First in Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients with COVID‐19

(2021) Peter Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rapid cGMP manufacturing of COVID‐19 monoclonal antibody using stable CHO cell pools

(2021) Rita Agostinetto et al.   BIOTECHNOLOGY AND BIOENGINEERING

Developing therapeutic monoclonal antibodies at pandemic pace

(2020) Brian Kelley   NATURE BIOTECHNOLOGY

Systematic identification of safe harbor regions in the CHO genome through a comprehensive epigenome analysis

(2020) William Hilliard et al.   BIOTECHNOLOGY AND BIOENGINEERING

Systematic Evaluation of Site-Specific Recombinant Gene Expression for Programmable Mammalian Cell Engineering

(2019) Nuša Pristovšek et al.   ACS Synthetic Biology

Considering “clonality”: A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development

(2019) Joel T. Welch et al.   BIOLOGICALS

The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem

(2019) Hussain Dahodwala et al.   CURRENT OPINION IN BIOTECHNOLOGY

Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System

(2018) Sowmya Balasubramanian et al.   Biotechnology Journal

Short- and long-term effects on mAb-producing CHO cell lines after cryopreservation

(2018) Jayashree Subramanian et al.   BIOTECHNOLOGY PROGRESS

Comprehensive characterization of glutamine synthetase-mediated selection for the establishment of recombinant CHO cells producing monoclonal antibodies

(2018) Soo Min Noh et al.   Scientific Reports

Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System

(2018) Sowmya Balasubramanian et al.   Biotechnology Journal

Recurring Genomic Structural Variation Leads to Clonal Instability and Loss of Productivity

(2018) Arpan A. Bandyopadhyay et al.   BIOTECHNOLOGY AND BIOENGINEERING

Minimizing Clonal Variation during Mammalian Cell Line Engineering for Improved Systems Biology Data Generation

(2018) Lise Marie Grav et al.   ACS Synthetic Biology

Biopharmaceutical benchmarks 2018

(2018) Gary Walsh   NATURE BIOTECHNOLOGY

Site-specific integration ushers in a new era of precise CHO cell line engineering

(2018) Nathaniel K Hamaker et al.   Current Opinion in Chemical Engineering

Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and early-phase trials by transient gene expression or stable pools

(2018) Matthew Stuible et al.   Current Opinion in Chemical Engineering

Cloning of CHO Cells, Productivity and Genetic Stability—A Discussion

(2017) Florian Wurm et al.   Processes

Industry view on the relative importance of “clonality” of biopharmaceutical-producing cell lines

(2016) Christopher Frye et al.   BIOLOGICALS

Bezlotoxumab: First Global Approval

(2016) Anthony Markham   DRUGS

Biopharmaceutical benchmarks 2014

(2014) Gary Walsh   NATURE BIOTECHNOLOGY

Anthrax drug first antibacterial mAb to win approval

(2013) Jeffrey L Fox   NATURE BIOTECHNOLOGY

Determination of Chinese hamster ovary cell line stability and recombinant antibody expression during long-term culture

(2012) Laura A Bailey et al.   BIOTECHNOLOGY AND BIOENGINEERING

A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies

(2011) Minsoo Kim et al.   BIOTECHNOLOGY AND BIOENGINEERING

Early prediction of instability of chinese hamster ovary cell lines expressing recombinant antibodies and antibody-fusion proteins

(2011) Haimanti Dorai et al.   BIOTECHNOLOGY AND BIOENGINEERING